Producer
Pfizer (Hospira)
Sterile injectables (Hospira) including propofol/anesthetics.
2
Inputs supplied
2
Goods downstream
0
Facilities
0
Stories
What they make
2 inputs Pfizer (Hospira) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Pfizer (Hospira) makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Hospira Sterile Injectables
Biosimilars
Pfizer Branded (parent)
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Chokepoint2023
Hospira's plant in Rocky Mount, North Carolina is one of the largest sterile-injectable manufacturing sites in the world, producing a substantial share of the generic injectable drugs used in U.S. hospitals. That concentration became a national vulnerability in July 2023, when a tornado struck the Rocky Mount facility, damaging it and disrupting output of dozens of critical injectables — worsening already severe shortages of hospital drugs across the country. A single weather event at one plant in one American town measurably tightened the national supply of life-critical medicines. It is one of the clearest illustrations in all of healthcare of a single-site chokepoint: when so much sterile-injectable capacity is concentrated in a handful of plants, the failure of just one can ripple into shortages at thousands of hospitals. [verify: July2023 tornado + single-site concentration confirmed; mainly warehouse hit, but worsened injectable shortages]
Pfizer Inc. (PFE) ↗Did you know2024
Pfizer is synonymous with blockbuster branded medicines and, since 2020, the COVID-19 vaccine. Far less visible is that the same company is one of the largest makers of cheap generic injectable hospital drugs — propofol, anesthetics, emergency crash-cart medicines, generic chemotherapy vials and IV fluids — through its 2015 acquisition of Hospira. These are the unglamorous, low-margin, hard-to-make sterile products that don't carry the Pfizer brand to patients but quietly keep operating rooms and ICUs running. So the company famous for the most lucrative end of pharma also occupies the least lucrative, most shortage-prone end of it. The maker of a global vaccine is, in another division, the maker of the no-name vials hanging from hospital IV poles — two opposite faces of the drug supply inside one corporation.
Pfizer Inc. (PFE) ↗Origin2024
Hospira didn't start as an independent company — it was spun out of Abbott Laboratories in 2004, carrying with it Abbott's decades-old hospital-products and intravenous-solutions business (Abbott had been a pioneer of IV fluids since the early 20th century). The name "Hospira" was coined to evoke "hospital," "spirit" and "hope." For a decade it was the largest dedicated generic-injectables and infusion company in the U.S., before Pfizer bought it in 2015 for roughly $17 billion — partly to gain a foothold in biosimilars and partly to acquire exactly this sterile-injectable and infusion capacity. So a core piece of America's hospital drug supply traces back through a 2004 Abbott spinoff to Abbott's century-old IV-fluids heritage, now operating as an arm of Pfizer.
Pfizer Inc. (PFE) ↗